126 related articles for article (PubMed ID: 33394043)
1. HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?
Shofuda T; Kanemura Y
Neuro Oncol; 2021 Feb; 23(2):173-174. PubMed ID: 33394043
[No Abstract] [Full Text] [Related]
2. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
3. Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.
Ecker J; Thatikonda V; Sigismondo G; Selt F; Valinciute G; Oehme I; Müller C; Buhl JL; Ridinger J; Usta D; Qin N; van Tilburg CM; Herold-Mende C; Remke M; Sahm F; Westermann F; Kool M; Wechsler-Reya RJ; Chavez L; Krijgsveld J; Jäger N; Pfister SM; Witt O; Milde T
Neuro Oncol; 2021 Feb; 23(2):226-239. PubMed ID: 32822486
[TBL] [Abstract][Full Text] [Related]
4. Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells.
Zeuner S; Vollmer J; Sigaud R; Oppermann S; Peterziel H; ElHarouni D; Oehme I; Witt O; Milde T; Ecker J
J Neurooncol; 2024 Jan; 166(1):99-112. PubMed ID: 38184819
[TBL] [Abstract][Full Text] [Related]
5. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG
Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741
[TBL] [Abstract][Full Text] [Related]
8. Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells.
Vollmer J; Ecker J; Hielscher T; Valinciute G; Ridinger J; Jamaladdin N; Peterziel H; van Tilburg CM; Oehme I; Witt O; Milde T
J Neurooncol; 2023 Sep; 164(3):617-632. PubMed ID: 37783879
[TBL] [Abstract][Full Text] [Related]
9. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
[TBL] [Abstract][Full Text] [Related]
10. OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.
Xu Z; Murad N; Malawsky D; Tao R; Rivero-Hinojosa S; Holdhof D; Schüller U; Zhang P; Lazarski C; Rood BR; Packer R; Gershon T; Pei Y
Clin Cancer Res; 2022 Oct; 28(19):4278-4291. PubMed ID: 35736214
[TBL] [Abstract][Full Text] [Related]
11. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
[TBL] [Abstract][Full Text] [Related]
12. Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells.
Valinciute G; Ecker J; Selt F; Hielscher T; Sigaud R; Ridinger J; Thatikonda V; Gatzweiler C; Robinson S; Talbot J; Bernardi F; Picard D; Blattner-Johnson M; Schmid S; Jones DT; van Tilburg CM; Capper D; Kool M; Remke M; Oehme I; Pfister SM; Roussel MF; Ayrault O; Witt O; Milde T
J Neurooncol; 2023 May; 163(1):143-158. PubMed ID: 37183219
[TBL] [Abstract][Full Text] [Related]
13. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma.
Bandopadhayay P; Piccioni F; O'Rourke R; Ho P; Gonzalez EM; Buchan G; Qian K; Gionet G; Girard E; Coxon M; Rees MG; Brenan L; Dubois F; Shapira O; Greenwald NF; Pages M; Balboni Iniguez A; Paolella BR; Meng A; Sinai C; Roti G; Dharia NV; Creech A; Tanenbaum B; Khadka P; Tracy A; Tiv HL; Hong AL; Coy S; Rashid R; Lin JR; Cowley GS; Lam FC; Goodale A; Lee Y; Schoolcraft K; Vazquez F; Hahn WC; Tsherniak A; Bradner JE; Yaffe MB; Milde T; Pfister SM; Qi J; Schenone M; Carr SA; Ligon KL; Kieran MW; Santagata S; Olson JM; Gokhale PC; Jaffe JD; Root DE; Stegmaier K; Johannessen CM; Beroukhim R
Nat Commun; 2019 Jun; 10(1):2400. PubMed ID: 31160565
[TBL] [Abstract][Full Text] [Related]
14. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.
Hill RM; Kuijper S; Lindsey JC; Petrie K; Schwalbe EC; Barker K; Boult JK; Williamson D; Ahmad Z; Hallsworth A; Ryan SL; Poon E; Robinson SP; Ruddle R; Raynaud FI; Howell L; Kwok C; Joshi A; Nicholson SL; Crosier S; Ellison DW; Wharton SB; Robson K; Michalski A; Hargrave D; Jacques TS; Pizer B; Bailey S; Swartling FJ; Weiss WA; Chesler L; Clifford SC
Cancer Cell; 2015 Jan; 27(1):72-84. PubMed ID: 25533335
[TBL] [Abstract][Full Text] [Related]
15. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
[TBL] [Abstract][Full Text] [Related]
16. Targeting HDAC And PI3K Inhibits MYC-Driven Medulloblastoma Growth.
Cancer Discov; 2016 May; 6(5):OF10. PubMed ID: 27012830
[TBL] [Abstract][Full Text] [Related]
17. HDAC inhibitors to the rescue in sonic hedgehog medulloblastoma.
Becher OJ
Neuro Oncol; 2019 Sep; 21(9):1091-1092. PubMed ID: 31242287
[No Abstract] [Full Text] [Related]
18. Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma.
Bharambe HS; Joshi A; Yogi K; Kazi S; Shirsat NV
Acta Neuropathol Commun; 2020 May; 8(1):70. PubMed ID: 32410663
[TBL] [Abstract][Full Text] [Related]
19. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
Milde T; Lodrini M; Savelyeva L; Korshunov A; Kool M; Brueckner LM; Antunes AS; Oehme I; Pekrun A; Pfister SM; Kulozik AE; Witt O; Deubzer HE
J Neurooncol; 2012 Dec; 110(3):335-48. PubMed ID: 23054560
[TBL] [Abstract][Full Text] [Related]
20. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Marquardt V; Theruvath J; Pauck D; Picard D; Qin N; Blümel L; Maue M; Bartl J; Ahmadov U; Langini M; Meyer FD; Cole A; Cruz-Cruz J; Graef CM; Wölfl M; Milde T; Witt O; Erdreich-Epstein A; Leprivier G; Kahlert U; Stefanski A; Stühler K; Keir ST; Bigner DD; Hauer J; Beez T; Knobbe-Thomsen CB; Fischer U; Felsberg J; Hansen FK; Vibhakar R; Venkatraman S; Cheshier SH; Reifenberger G; Borkhardt A; Kurz T; Remke M; Mitra S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
